Developer docs
API playgroundTry for free, no card

Search company profiles

Idorsia

Full company profile

uuid00009sm

Namestring
Idorsia
Legal namestring
Idorsia Pharmaceuticals Ltd
Websiteurl
idorsia.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Idorsia Pharmaceuticals Ltd is a Swiss biopharmaceutical company founded in 2017 through the demerger of Actelion's drug discovery and early-stage clinical pipeline into a publicly listed entity on the SIX Swiss Exchange (ticker: IDIA). Headquartered in Allschwil, the company employs approximately 500 staff across 14 sites in Europe, North America, and Asia, and operates a research, development, and commercialization platform focused on small-molecule medicines for central nervous system, cardiovascular, immunological, and rare diseases. Idorsia's core technology centers on novel mechanisms of action, including dual orexin receptor antagonism (daridorexant), dual endothelin receptor antagonism (aprocitentan), and a synthetic glycan-based glycoconjugate vaccine platform.

The company has transitioned from an R&D-stage to a commercial-stage biopharmaceutical, with three core marketed brands: QUVIVIQ (daridorexant) for chronic insomnia, approved in the US, EU, Canada, Switzerland, China, and 13 European countries; TRYVIO (aprocitentan) in the US; and JERAYGO (aprocitentan) in the EU/UK/Switzerland for resistant hypertension. Idorsia generates revenue from direct product sales in the US, Canada, and major European markets, complemented by a layered partnership model: Syneos Health operates approximately 20 US virtual sales representatives, Menarini/Berlin-Chemie extend reach to general practitioners in Europe, while Nxera Pharma (APAC ex-China), Simcere (China), Pharmalink (GCC), and EMS (LATAM) handle regional commercialization. A second revenue stream comprises licensing milestones and royalties, including a USD 350 million upfront and development cost-sharing under the Viatris collaboration for selatogrel and cenerimod, plus tiered royalties on Simcere's QUVIVIQ sales in China and Santhera vamorolone royalties.

FY2025 total revenue reached CHF 214 million (+89% YoY), driven by QUVIVIQ net product sales of CHF 134 million (more than double the CHF 61 million in 2024) and 2026 QUVIVIQ sales are guided to CHF 200 million. The company continues to operate at a net loss, though the US GAAP net loss narrowed sharply to CHF 112 million in 2025 from CHF 264 million in 2024, and non-GAAP operating loss improved 67% to CHF 100 million. Capital structure remains leveraged, with CHF 1,395 million of total indebtedness and CHF 95 million of liquidity as of March 31, 2026, partially offset by a new CHF 250 million Pharmakon/BioPharma Credit senior secured facility maturing in June 2031 and a CHF 65.6 million equity raise completed in October 2025.

Short descriptiontext

Idorsia Pharmaceuticals is a Swiss biopharmaceutical company that discovers, develops, and commercializes small-molecule drugs for insomnia, resistant hypertension, Fabry disease, and rare disorders, with marketed products QUVIVIQ, TRYVIO, and JERAYGO sold globally via direct affiliates and regional partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAllschwil, Switzerland
HQ citystring
Allschwil
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices13 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
insomnia therapeutics, hypertension treatments, rare disease therapies, small molecule drugs, CNS pharmaceuticals
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Specialty Pharmaceuticals
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Product Sales - QUVIVIQ (daridorexant)
TypeOne Time License
Description

Direct product sales of QUVIVIQ for insomnia in markets where Idorsia has commercial operations (US, major European countries, Canada). Net sales reached CHF 134 million in 2025, with projected sales of CHF 200 million in 2026.

2Product Sales - TRYVIO/JERAYGO (aprocitentan)
TypeOne Time License
Description

Sales of aprocitentan for hypertension in the US (TRYVIO) and Europe (JERAYGO for resistant hypertension).

idorsia.com
3Licensing and Milestone Payments
TypeLicensing Royalties
Description

Upfront payments, development and regulatory milestones, and sales milestones from partners including Viatris (selatogrel, cenerimod), Simcere (daridorexant in China), Nxera Pharma (Asia Pacific), and others. Received USD 350 million upfront from Viatris, USD 230 million milestone from Janssen for aprocitentan approval.

idorsia.com
4Royalty Revenue
TypeLicensing Royalties
Description

Royalties from partnered products including low- to mid-single digit royalties on aprocitentan net sales, tiered royalties on daridorexant sales in China (low- to high-single digit), and royalties on vamorolone sales from Santhera.

idorsia.com
5Contract Revenue
TypeManaged Services
Description

Revenue from development cost-sharing arrangements with partners, such as the Viatris collaboration for selatogrel and cenerimod development.

idorsia.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1QUVIVIQ (daridorexant) available in 25mg and 50mg doses
ModelOtherBilling cadenceMonthly
Notes

Pricing determined by market-specific reimbursement and pharmacy pricing. Available by prescription only.

idorsia.com
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1QUVIVIQ (daridorexant)
Description

Dual orexin receptor antagonist for treatment of insomnia; approved in US, Europe, Canada, and multiple other countries

idorsia.com
+2 more records
Core offering1 text field

Idorsia is a Swiss biopharmaceutical company that discovers, develops, and commercializes innovative small-molecule medicines with novel mechanisms of action across CNS, cardiovascular, and rare disease therapeutic areas. Its commercial products include QUVIVIQ (daridorexant) for chronic insomnia and TRYVIO/JERAYGO (aprocitentan) for resistant hypertension, with a pipeline spanning Fabry disease (lucerastat), systemic lupus erythematosus (cenerimod), acute myocardial infarction (selatogrel), and synthetic glycan-based vaccines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • QUVIVIQ demonstrated statistically significant dose-dependent improvement in total sleep time (p=0.0185) in pediatric patients aged 10-17 years with insomnia disorder
+4 more records
Product and service4 records
1QUVIVIQ (daridorexant)
CategoryInsomnia Therapeutics
2TRYVIO (aprocitentan)
CategoryAntihypertensive Therapeutics
3JERAYGO (aprocitentan)
CategoryAntihypertensive Therapeutics
4Lucerastat
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-01
Description

Exclusive agreement with Pharmalink Drug Store for distribution and commercialization of QUVIVIQ in Kuwait, Oman, Qatar, Bahrain, and UAE. Idorsia retains marketing authorizations, receives upfront payment, and supplies finished product at pre-determined price. Pharmalink handles local sales, promotion, and distribution.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Partnership with EMS S.A. to bring QUVIVIQ to Latin America following regulatory submission in Brazil. Collaboration includes responsibilities for registration, commercialization, and milestone payments as part of Idorsia's global expansion.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-01
Description

Commercial partnership with Menarini in France for QUVIVIQ, expanding reach from specialist prescribers to general practitioners in October 2024. Partnership substantially increased sales quarter on quarter, with France becoming one of the main drivers of sales growth in the EUCAN region.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-04-01
Description

Commercial partnership with Berlin-Chemie, a wholly owned subsidiary of Menarini Group, for QUVIVIQ commercialization from specialist to general practitioner channels beginning early April 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-01
Description

Global R&D collaboration with Viatris for development and commercialization rights to selatogrel (acute myocardial infarction) and cenerimod (systemic lupus erythematosus). Idorsia received USD 350 million upfront with obligation to contribute USD 200 million for development. Updated terms in February 2025 reduced Idorsia's contribution to USD 100 million with USD 250 million reduction in future milestone payments and expanded territorial rights for cenerimod to Viatris.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Owkin has global license to develop and commercialize ACT-1002-4391, Idorsia's novel EP2/EP4 receptor antagonist with antitumor efficacy. Owkin will use its proprietary AI-based data-mining platform to generate clinical trial designs and identify patients who may benefit.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-01-01
Description

Idorsia sold its Asia Pacific (ex-China) operations to Nxera Pharma for total consideration of CHF 400 million. Transaction includes acquisition of affiliates in Japan and South Korea, assignment of PIVLAZ license, co-exclusive license for daridorexant in the territory, and option to license lucerastat. Territory: Australia, Brunei, Cambodia, Indonesia, Japan, South Korea, Malaysia, Myanmar, New Zealand, Philippines, Singapore, Thailand, Taiwan, Vietnam.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-01-01
Description

Exclusive licensing agreement for daridorexant in Greater China region. Simcere received USD 30 million upfront and successfully commercialized Sanbexin for acute ischemic stroke. In June 2025, Simcere received Chinese NMPA approval for QUVIVIQ and Idorsia received USD 50 million approval milestone. Updated terms include milestone payments up to USD 93 million and low- to high-single digit tiered royalties on future net sales.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-01-01
Description

Innovative commercial partnership for US launch of QUVIVIQ. Syneos Health provides approximately 20 virtual sales representatives operating with data-driven targeted call plans, replacing approximately 100 field force reps. Expanded in January 2022 to support potential launch in Europe and Canada. Syneos executes marketing, focused digital media, data analytics, and market access activities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-12-01
Description

Collaboration agreement with Janssen Biotech for jointly developing aprocitentan and derivative compounds. Janssen had sole worldwide commercialization rights. In September 2023, Idorsia reacquired development and commercialization rights from Janssen. Idorsia paid USD 230 million milestone and will pay conditional consideration up to CHF 306 million (30% of out-licensing consideration, 10% of other product considerations, low- to mid-single digit royalties on net sales). Janssen retains licenses in pulmonary hypertension.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Eisai
TypeDirect peer
Description

Eisai markets Dayvigo (lemborexant), another dual orexin receptor antagonist for insomnia that directly competes with Idorsia's QUVIVIQ. Both companies target the same patient population and prescriber base (sleep specialists and primary care), with Eisai having a larger established commercial infrastructure in the US and Japan.

TypeDirect peer
Description

Lundbeck is a Danish specialty pharmaceutical company focused on CNS disorders including insomnia, depression, and neurology. Its portfolio overlaps directly with Idorsia's CNS focus, and its European commercial scale provides a comparable benchmark for QUVIVIQ's European rollout and CNS market dynamics.

TypeBroad incumbent
Description

Sanofi markets Fabrazyme (agalsidase beta) for Fabry disease, directly competing with lucerastat, and has broader cardiovascular and rare disease franchises overlapping with aprocitentan. As a top-5 global pharma, Sanofi represents a broad incumbent comparable for Idorsia's specialty therapeutic areas.

TypeBroad incumbent
Description

Bayer is a major player in cardiovascular pharmaceuticals with established hypertension franchises (Xarelto, Adempas). As a broad incumbent in cardiovascular medicine, Bayer provides a relevant comparable for aprocitentan's market opportunity and commercial dynamics in resistant hypertension.

TypeRegional player
Description

Sumitomo Pharma (formerly Sumitomo Dainippon) markets sleep disorder and CNS therapeutics in Japan and APAC markets. Its regional focus in APAC mirrors Idorsia's APAC partnership with Nxera Pharma and provides comparable insights into Japanese insomnia market dynamics.

TypeDirect peer
Description

Jazz Pharmaceuticals is a specialty pharma company with CNS and rare disease franchises including sleep disorder treatments. Its commercial model for narcolepsy drugs (Xywav, Xyrem) and CNS specialty focus makes it directly comparable to Idorsia's QUVIVIQ franchise in the sleep medicine specialist channel.

TypeEmerging player
Description

Viatris is Idorsia's R&D collaboration partner for selatogrel and cenerimod, providing comparable scale in specialty pharmaceuticals. As a global specialty pharma formed from Mylan/Pfizer Upjohn combination, Viatris offers insights into commercial scaling and pricing dynamics in Idorsia's target therapeutic areas.

TypeDirect peer
Description

BioMarin is a rare disease specialty pharmaceutical company with comparable size and therapeutic focus on genetic disorders. Its commercial execution in orphan diseases provides a relevant benchmark for Idorsia's Fabry disease and rare disease strategy.

TypeDirect peer
Description

Amicus markets Galafold (migalastat) for Fabry disease, directly competing with Idorsia's lucerastat in the same rare disease indication. Both companies target Fabry patients with novel oral mechanisms, providing a direct comparable for market sizing, pricing dynamics, and rare disease commercial execution.

TypeRegional player
Description

Recordati is a European specialty pharmaceutical company with established cardiovascular and rare disease franchises. Its primary geographic focus on Europe mirrors Idorsia's EUCAN commercial operations and provides a relevant benchmark for European specialty pharma execution.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries13 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Idorsia

Specialty Pharmaceuticalsidorsia.com

Idorsia Pharmaceuticals is a Swiss biopharmaceutical company that discovers, develops, and commercializes small-molecule drugs for insomnia, resistant hypertension, Fabry disease, and rare disorders, with marketed products QUVIVIQ, TRYVIO, and JERAYGO sold globally via direct affiliates and regional partners.

What Idorsia does

Idorsia Pharmaceuticals Ltd is a Swiss biopharmaceutical company founded in 2017 through the demerger of Actelion's drug discovery and early-stage clinical pipeline into a publicly listed entity on the SIX Swiss Exchange (ticker: IDIA). Headquartered in Allschwil, the company employs approximately 500 staff across 14 sites in Europe, North America, and Asia, and operates a research, development, and commercialization platform focused on small-molecule medicines for central nervous system, cardiovascular, immunological, and rare diseases. Idorsia's core technology centers on novel mechanisms of action, including dual orexin receptor antagonism (daridorexant), dual endothelin receptor antagonism (aprocitentan), and a synthetic glycan-based glycoconjugate vaccine platform.

The company has transitioned from an R&D-stage to a commercial-stage biopharmaceutical, with three core marketed brands: QUVIVIQ (daridorexant) for chronic insomnia, approved in the US, EU, Canada, Switzerland, China, and 13 European countries; TRYVIO (aprocitentan) in the US; and JERAYGO (aprocitentan) in the EU/UK/Switzerland for resistant hypertension. Idorsia generates revenue from direct product sales in the US, Canada, and major European markets, complemented by a layered partnership model: Syneos Health operates approximately 20 US virtual sales representatives, Menarini/Berlin-Chemie extend reach to general practitioners in Europe, while Nxera Pharma (APAC ex-China), Simcere (China), Pharmalink (GCC), and EMS (LATAM) handle regional commercialization. A second revenue stream comprises licensing milestones and royalties, including a USD 350 million upfront and development cost-sharing under the Viatris collaboration for selatogrel and cenerimod, plus tiered royalties on Simcere's QUVIVIQ sales in China and Santhera vamorolone royalties.

FY2025 total revenue reached CHF 214 million (+89% YoY), driven by QUVIVIQ net product sales of CHF 134 million (more than double the CHF 61 million in 2024) and 2026 QUVIVIQ sales are guided to CHF 200 million. The company continues to operate at a net loss, though the US GAAP net loss narrowed sharply to CHF 112 million in 2025 from CHF 264 million in 2024, and non-GAAP operating loss improved 67% to CHF 100 million. Capital structure remains leveraged, with CHF 1,395 million of total indebtedness and CHF 95 million of liquidity as of March 31, 2026, partially offset by a new CHF 250 million Pharmakon/BioPharma Credit senior secured facility maturing in June 2031 and a CHF 65.6 million equity raise completed in October 2025.

Idorsia firmographics

Firmographics
Name
Idorsia
Legal name
Idorsia Pharmaceuticals Ltd
Website
https://idorsia.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Idorsia Pharmaceuticals is a Swiss biopharmaceutical company that discovers, develops, and commercializes small-molecule drugs for insomnia, resistant hypertension, Fabry disease, and rare disorders, with marketed products QUVIVIQ, TRYVIO, and JERAYGO sold globally via direct affiliates and regional partners.
Ownership category
akta.pro rank

Idorsia industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals

Keywords

  • Insomnia therapeutics
  • Hypertension treatments
  • Rare disease therapies
  • Small molecule drugs
  • CNS pharmaceuticals

Where Idorsia is headquartered

Location

Headquarters

HQ city
Allschwil
HQ country
Switzerland
HQ region
Europe

Offices13 records

Markets served

Idorsia business model

Business model
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Product Sales - QUVIVIQ (daridorexant): Direct product sales of QUVIVIQ for insomnia in markets where Idorsia has commercial operations (US, major European countries, Canada). Net sales reached CHF 134 million in 2025, with projected sales of CHF 200 million in 2026.
  2. Product Sales - TRYVIO/JERAYGO (aprocitentan): Sales of aprocitentan for hypertension in the US (TRYVIO) and Europe (JERAYGO for resistant hypertension).
  3. Licensing and Milestone Payments: Upfront payments, development and regulatory milestones, and sales milestones from partners including Viatris (selatogrel, cenerimod), Simcere (daridorexant in China), Nxera Pharma (Asia Pacific), and others. Received USD 350 million upfront from Viatris, USD 230 million milestone from Janssen for aprocitentan approval.
  4. Royalty Revenue: Royalties from partnered products including low- to mid-single digit royalties on aprocitentan net sales, tiered royalties on daridorexant sales in China (low- to high-single digit), and royalties on vamorolone sales from Santhera.
  5. Contract Revenue: Revenue from development cost-sharing arrangements with partners, such as the Viatris collaboration for selatogrel and cenerimod development.

Pricing tiers

ModelBillingPrice
OtherMonthlyQUVIVIQ (daridorexant) available in 25mg and 50mg doses

Go-to-market motion3 records

Distribution channels7 records

Marketing channels5 records

Idorsia product offering

Product offering

Core offering

Idorsia is a Swiss biopharmaceutical company that discovers, develops, and commercializes innovative small-molecule medicines with novel mechanisms of action across CNS, cardiovascular, and rare disease therapeutic areas. Its commercial products include QUVIVIQ (daridorexant) for chronic insomnia and TRYVIO/JERAYGO (aprocitentan) for resistant hypertension, with a pipeline spanning Fabry disease (lucerastat), systemic lupus erythematosus (cenerimod), acute myocardial infarction (selatogrel), and synthetic glycan-based vaccines.

Differentiator

Problem solved

Functional benefit

Brands

  • QUVIVIQ (daridorexant): Dual orexin receptor antagonist for treatment of insomnia; approved in US, Europe, Canada, and multiple other countries
  • TRYVIO (aprocitentan)
  • JERAYGO (aprocitentan)

Products and services

  • QUVIVIQ (daridorexant)
  • TRYVIO (aprocitentan)
  • JERAYGO (aprocitentan)
  • Lucerastat

Quantifiable outcome

  • QUVIVIQ demonstrated statistically significant dose-dependent improvement in total sleep time (p=0.0185) in pediatric patients aged 10-17 years with insomnia disorder
  • +4 more outcomes

Companies that use Idorsia

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Idorsia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Idorsia partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered regional, major, core and strategic.

  • PharmalinkregionalChannel Partner/ Reseller/ Distributor · 1 March 2026Exclusive agreement with Pharmalink Drug Store for distribution and commercialization of QUVIVIQ in Kuwait, Oman, Qatar, Bahrain, and UAE. Idorsia retains marketing authorizations, receives upfront payment, and supplies finished product at pre-determined price. Pharmalink handles local sales, promotion, and distribution.
  • EMS S.A.regionalChannel Partner/ Reseller/ Distributor · 1 January 2026Partnership with EMS S.A. to bring QUVIVIQ to Latin America following regulatory submission in Brazil. Collaboration includes responsibilities for registration, commercialization, and milestone payments as part of Idorsia's global expansion.
  • Menarini FrancemajorChannel Partner/ Reseller/ Distributor · 1 October 2025Commercial partnership with Menarini in France for QUVIVIQ, expanding reach from specialist prescribers to general practitioners in October 2024. Partnership substantially increased sales quarter on quarter, with France becoming one of the main drivers of sales growth in the EUCAN region.
  • Berlin Chemie (Menarini Group)majorChannel Partner/ Reseller/ Distributor · 1 April 2025Commercial partnership with Berlin-Chemie, a wholly owned subsidiary of Menarini Group, for QUVIVIQ commercialization from specialist to general practitioner channels beginning early April 2025.
  • ViatriscoreStrategic or Co-development Partner · 1 March 2024Global R&D collaboration with Viatris for development and commercialization rights to selatogrel (acute myocardial infarction) and cenerimod (systemic lupus erythematosus). Idorsia received USD 350 million upfront with obligation to contribute USD 200 million for development. Updated terms in February 2025 reduced Idorsia's contribution to USD 100 million with USD 250 million reduction in future milestone payments and expanded territorial rights for cenerimod to Viatris.
  • OwkinstrategicTechnology or Integration · 1 January 2024Owkin has global license to develop and commercialize ACT-1002-4391, Idorsia's novel EP2/EP4 receptor antagonist with antitumor efficacy. Owkin will use its proprietary AI-based data-mining platform to generate clinical trial designs and identify patients who may benefit.
  • Nxera PharmacoreChannel Partner/ Reseller/ Distributor · 1 January 2023Idorsia sold its Asia Pacific (ex-China) operations to Nxera Pharma for total consideration of CHF 400 million. Transaction includes acquisition of affiliates in Japan and South Korea, assignment of PIVLAZ license, co-exclusive license for daridorexant in the territory, and option to license lucerastat. Territory: Australia, Brunei, Cambodia, Indonesia, Japan, South Korea, Malaysia, Myanmar, New Zealand, Philippines, Singapore, Thailand, Taiwan, Vietnam.
  • SimcerecoreChannel Partner/ Reseller/ Distributor · 1 January 2022Exclusive licensing agreement for daridorexant in Greater China region. Simcere received USD 30 million upfront and successfully commercialized Sanbexin for acute ischemic stroke. In June 2025, Simcere received Chinese NMPA approval for QUVIVIQ and Idorsia received USD 50 million approval milestone. Updated terms include milestone payments up to USD 93 million and low- to high-single digit tiered royalties on future net sales.
  • Syneos HealthmajorChannel Partner/ Reseller/ Distributor · 1 January 2020Innovative commercial partnership for US launch of QUVIVIQ. Syneos Health provides approximately 20 virtual sales representatives operating with data-driven targeted call plans, replacing approximately 100 field force reps. Expanded in January 2022 to support potential launch in Europe and Canada. Syneos executes marketing, focused digital media, data analytics, and market access activities.
  • Johnson & Johnson Innovative Medicine (Janssen)coreStrategic or Co-development Partner · 1 December 2017Collaboration agreement with Janssen Biotech for jointly developing aprocitentan and derivative compounds. Janssen had sole worldwide commercialization rights. In September 2023, Idorsia reacquired development and commercialization rights from Janssen. Idorsia paid USD 230 million milestone and will pay conditional consideration up to CHF 306 million (30% of out-licensing consideration, 10% of other product considerations, low- to mid-single digit royalties on net sales). Janssen retains licenses in pulmonary hypertension.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Idorsia competitors and assessment

Company assessment

Direct peers

  • Eisai: Eisai markets Dayvigo (lemborexant), another dual orexin receptor antagonist for insomnia that directly competes with Idorsia's QUVIVIQ. Both companies target the same patient population and prescriber base (sleep specialists and primary care), with Eisai having a larger established commercial infrastructure in the US and Japan.
  • Lundbeck: Lundbeck is a Danish specialty pharmaceutical company focused on CNS disorders including insomnia, depression, and neurology. Its portfolio overlaps directly with Idorsia's CNS focus, and its European commercial scale provides a comparable benchmark for QUVIVIQ's European rollout and CNS market dynamics.
  • Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharma company with CNS and rare disease franchises including sleep disorder treatments. Its commercial model for narcolepsy drugs (Xywav, Xyrem) and CNS specialty focus makes it directly comparable to Idorsia's QUVIVIQ franchise in the sleep medicine specialist channel.
  • BioMarin Pharmaceutical: BioMarin is a rare disease specialty pharmaceutical company with comparable size and therapeutic focus on genetic disorders. Its commercial execution in orphan diseases provides a relevant benchmark for Idorsia's Fabry disease and rare disease strategy.
  • Amicus Therapeutics: Amicus markets Galafold (migalastat) for Fabry disease, directly competing with Idorsia's lucerastat in the same rare disease indication. Both companies target Fabry patients with novel oral mechanisms, providing a direct comparable for market sizing, pricing dynamics, and rare disease commercial execution.

Broad incumbents

  • Sanofi: Sanofi markets Fabrazyme (agalsidase beta) for Fabry disease, directly competing with lucerastat, and has broader cardiovascular and rare disease franchises overlapping with aprocitentan. As a top-5 global pharma, Sanofi represents a broad incumbent comparable for Idorsia's specialty therapeutic areas.
  • Bayer: Bayer is a major player in cardiovascular pharmaceuticals with established hypertension franchises (Xarelto, Adempas). As a broad incumbent in cardiovascular medicine, Bayer provides a relevant comparable for aprocitentan's market opportunity and commercial dynamics in resistant hypertension.

Regional players

  • Sumitomo Pharma: Sumitomo Pharma (formerly Sumitomo Dainippon) markets sleep disorder and CNS therapeutics in Japan and APAC markets. Its regional focus in APAC mirrors Idorsia's APAC partnership with Nxera Pharma and provides comparable insights into Japanese insomnia market dynamics.
  • Recordati: Recordati is a European specialty pharmaceutical company with established cardiovascular and rare disease franchises. Its primary geographic focus on Europe mirrors Idorsia's EUCAN commercial operations and provides a relevant benchmark for European specialty pharma execution.

Emerging players

  • Viatris: Viatris is Idorsia's R&D collaboration partner for selatogrel and cenerimod, providing comparable scale in specialty pharmaceuticals. As a global specialty pharma formed from Mylan/Pfizer Upjohn combination, Viatris offers insights into commercial scaling and pricing dynamics in Idorsia's target therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Idorsia social profiles

Digital presence

Idorsia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Idorsia leadership team

Management profile

Number of profiles

Profiles13 records

Idorsia subsidiaries and ownership

Company hierarchy

Subsidiaries13 records

Idorsia funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Idorsia M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Idorsia

What does Idorsia do?

Idorsia is a Swiss biopharmaceutical company that discovers, develops, and commercializes innovative small-molecule medicines with novel mechanisms of action across CNS, cardiovascular, and rare disease therapeutic areas. Its commercial products include QUVIVIQ (daridorexant) for chronic insomnia and TRYVIO/JERAYGO (aprocitentan) for resistant hypertension, with a pipeline spanning Fabry disease (lucerastat), systemic lupus erythematosus (cenerimod), acute myocardial infarction (selatogrel), and synthetic glycan-based vaccines.

Is Idorsia a public or private company?

Idorsia is a public company. It is classified as public and is currently operating.

When was Idorsia founded?

Idorsia was founded in 2017. It employs 501 to 1,000 people.

Where is Idorsia based?

Idorsia is headquartered in Allschwil, Switzerland, in the Europe region.

How does Idorsia make money?

Five revenue lines are on record. Product Sales - QUVIVIQ (daridorexant) is the primary driver. The others are product Sales - TRYVIO/JERAYGO (aprocitentan), licensing and Milestone Payments, royalty Revenue and contract Revenue.

Who are Idorsia's main competitors?

Direct peers on record are Eisai, Lundbeck, Jazz Pharmaceuticals, BioMarin Pharmaceutical and Amicus Therapeutics. Broad incumbents are Sanofi and Bayer. Regional players are Sumitomo Pharma and Recordati. Viatris is listed as an emerging player.

Does Idorsia have an API?

No public API is recorded for Idorsia.

What industry is Idorsia in?

Idorsia's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIACAJ, Transplant & Immunosuppression Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaIdorsia Ltd (IDRSF) Shareholder/Analyst Call TranscriptIdorsia's CEO Roland Wandeler and management presented the company's strategy for a proposed commercialization partnership with SPV noteholders to unlock the value of Tryvio/Jeraygo. The partnership aims to unlock the blockbuster potential of the drug, with the company citing it as an attractive use of capital.The Pharma LetterFDA Breakthrough status for Idorsia’s daridorexantThe FDA granted Breakthrough Therapy designation to Idorsia's daridorexant for insomnia in children and adolescents aged 10 to under 18. The designation enables intensive FDA guidance and closer collaboration on development. Daridorexant is a dual orexin receptor antagonist with an optimized pharmacokinetic profile.Business & FinancialIdorsia And SPV Investors Partner To Unlock The Blockbuster Potential Of TRYVIO/JERAYGO With A Targeted Launch In SpecialistsIdorsia announced a proposed commercialization partnership with SPV noteholders to launch aprocitentan (TRYVIO/JERAYGO) in hypertension specialists. The deal includes CHF 120M in launch capital and a 30% global net revenue share for Idorsia, with breakeven projected in 2029.TradingViewIdorsia Ltd (IDIA) Sets CHF 120M SPV-Backed Plan to Launch TRYVIO/JERAYGOIdorsia announced a proposed SPV partnership to fund TRYVIO/JERAYGO commercialization with CHF 120M, split between noteholders and the company. The plan targets a specialist-focused launch with a projected breakeven in 2029 and Idorsia receiving 30% global net revenue.TradingViewIdorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialistsIdorsia announced a proposed commercialization partnership with SPV investors to launch TRYVIO/JERAYGO (aprocitentan) in specialists. The deal combines CHF 120 million in launch capital with a 30% global net revenue share for Idorsia, targeting resistant hypertension. The business plan projects breakeven in 2029.Business & FinancialIdorsia Initiates Pivotal Phase 3 Study For Lucerastat In Fabry Disease And Enters Co-Development And Commercialization Agreement With NxeraIdorsia initiated FAB-KLEAR, a pivotal Phase 3 kidney biopsy study of lucerastat in Fabry disease, and signed a co-development and commercialization agreement with Nxera. Nxera will pay CHF 7 million and hold exclusive rights in Japan and selected Asia Pacific territories, with a regulatory filing targeted for 2029.GlobeNewswireIdorsia initiates pivotal Phase 3 study for lucerastat in Fabry disease and enters co-development and commercialization agreement with NxeraIdorsia initiated FAB-KLEAR, a pivotal Phase 3 kidney biopsy study of lucerastat in Fabry disease, and signed a co-development and commercialization agreement with Nxera. Nxera will pay CHF 7 million and hold exclusive rights in Japan and selected Asia Pacific territories. The program targets a regulatory filing as early as 2029.GlobeNewswireIdorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-DreamIdorsia announced first patients enrolled in Dari-Dream, a US label-enabling study of QUVIVIQ 50 mg for insomnia. The Phase 3 study will evaluate daytime functioning, with results expected in 2028. Inclusion of daytime outcomes in US prescribing information is sought.The Pharma LetterIdorsia to advance daridorexant development in autism spectrum disorderIdorsia announced it is advancing a development program to investigate daridorexant in autism spectrum disorder, with shares rising 3.8% to 4.35 francs. The company is working on a dedicated formulation and discussing development design with global health authorities. Further details will be shared in the first half of 2027.The future of tradingIdorsia jumps after advancing study of autism spectrum disorder drug daridorexantIdorsia shares rose 5.1% in premarket trading after a Phase 2 pediatric insomnia study showed unexpected improvements in affect, behavior, cognition, and daily activities for children with autism spectrum disorder. The company expects to detail its development program in the first half of 2027 following health authority discussions.